Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes

被引:269
作者
Monnier, Louis [1 ]
Colette, Claude [1 ]
Wojtusciszyn, Anne [2 ]
Dejager, Sylvie [3 ]
Renard, Eric [2 ]
Molinari, Nicolas [4 ]
Owens, David R. [5 ]
机构
[1] Univ Montpellier, Inst Clin Res, Montpellier, France
[2] Univ Montpellier, Montpellier Univ Hosp, Dept Endocrinol Diabet & Nutr, Montpellier, France
[3] Hop La Pitie Salpetriere, Dept Endocrinol, Paris, France
[4] Univ Montpellier, Montpellier Univ Hosp, UMR 5149, Dept Stat & Epidemiol, Montpellier, France
[5] Swansea Univ, Diabet Res Grp, Swansea, W Glam, Wales
关键词
SILENT MYOCARDIAL-INFARCTION; CARDIOVASCULAR OUTCOMES; HEART-FAILURE; DOUBLE-BLIND; TYPE-2; LIRAGLUTIDE; EMPAGLIFLOZIN; RISK; DISEASE; INTERVENTION;
D O I
10.2337/dc16-1769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To define the threshold for excess glucose variability (GV), one of the main features of dysglycemia in diabetes. RESEARCH DESIGN AND METHODS A total of 376 persons with diabetes investigated at the University Hospital of Montpellier (Montpellier, France) underwent continuous glucose monitoring. Participants with type 2 diabetes were divided into several groups-groups 1, 2a, 2b, and 3 (n = 82, 28, 65, and 79, respectively)-according to treatment: 1) diet and/or insulin sensitizers alone; 2) oral therapy including an insulinotropic agent, dipeptidyl peptidase 4 inhibitors (group 2a) or sulfonylureas (group 2b); or 3) insulin. Group 4 included 122 persons with type 1 diabetes. Percentage coefficient of variation for glucose (% CV = [(SD of glucose)/(mean glucose)] 3 100) and frequencies of hypoglycemia (interstitial glucose < 56 mg/dL [3.1 mmol/L]) were computed. RESULTS Percentages of CV (median [interquartile range]; %) increased significantly (P < 0.0001) from group 1 (18.1 [15.2-23.9]) to group 4 (37.2 [31.0-42.3]). In group 1, the upper limit of % CV, which served as reference for defining excess GV, was 36%. Percentages of patients with % CVs above this threshold in groups 2a, 2b, 3, and 4 were 0, 12.3, 19.0, and 55.7%, respectively. Hypoglycemia was more frequent in group 2b (P < 0.01) and groups 3 and 4 (P < 0.0001) when subjects with a % CV > 36% were compared with those with % CV oe 36%. CONCLUSIONS A% CV of 36% appears to be a suitable threshold to distinguish between stable and unstable glycemia in diabetes because beyond this limit, the frequency of hypoglycemia is significantly increased, especially in insulin-treated subjects.
引用
收藏
页码:832 / 838
页数:7
相关论文
共 34 条
  • [1] American Diabetes Association, 2017, Diabetes Care, V40, pS88
  • [2] [Anonymous], 2008, GUID IND DIAB MELL C
  • [3] [Anonymous], FDA BRIEF DOC END ME
  • [4] Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Burgess, David C.
    Hunt, David
    Li, LiPing
    Zannino, Diana
    Williamson, Elizabeth
    Davis, Timothy M. E.
    Laakso, Markku
    Kesaniemi, Y. Antero
    Zhang, Jun
    Sy, Raymond W.
    Lehto, Seppo
    Mann, Stewart
    Keech, Anthony C.
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (01) : 92 - 99
  • [5] Committee for Medicinal Products for Human Use (CHMP) Medicines Agency E, 2012, GUID CLIN INV MED PR
  • [6] Diabetes Canada, 2016, PHARM MAN TYP 2 DIAB
  • [7] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [8] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
    Ferrannini, Ele
    Mark, Michael
    Mayoux, Eric
    [J]. DIABETES CARE, 2016, 39 (07) : 1108 - 1114
  • [9] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [10] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Gaede, P
    Vedel, P
    Larsen, N
    Jensen, GVH
    Parving, H
    Pedersen, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) : 383 - 393